A B S T R AC T
The genetics of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a complex area of investigation because of the low frequency of AAVs, the rarity of familial cases and the complexity of disease phenotypes. However, recent studies have been able to gather significant numbers of patients, and multicentre collaborative efforts have allowed the performance of two genome-wide association studies (GWASs). Genetic association studies based on candidate gene approaches and the two GWASs have greatly contributed to our current understanding of the genetic basis of AAV. The central role of autoimmunity has been confirmed by the significant association with HLA polymorphisms; interestingly, the three main AAV subtypes are associated with distinct HLA variants, i.e. granulomatosis with polyangiitis (Wegener's GPA) with HLA-DP1, microscopic polyangiitis with HLA-DQ and eosinophilic GPA (Churg-Strauss) with HLA-DRB4. GWASs also revealed that polymorphic variants of genes encoding proteinase 3 (PR3), the predominant antigenic target of ANCA in GPA, and its main inhibitor, alpha-1 antitrypsin, are highly associated with GPA and, even more significantly, with PR3-ANCA positivity (regardless of the clinical diagnosis); this emphasizes the central pathogenic role of PR3 and humoral autoimmunity in PR3-ANCA positive vasculitis. Finally, candidate gene approach studies have shown associations with other variants involved in autoimmunity, such as those belonging to the CTLA-4 and PTPN22 genes, although these findings warrant replication in larger studies. Additional studies are underway to better characterize disease associations within the AAV spectrum, which could provide new pathogenetic clues and possibly new treatment targets.
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I N T R O D U C T I O N
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) refers to a group of small-vessel vasculitis, including granulomatosis with polyangiitis (GPA, formerly known as Wegener's granulomatosis), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA, formerly ChurgStrauss syndrome) [1] . GPA and MPA are characterized by an extensive overlap in terms of clinical manifestations, mainly due to the possible vasculitic involvement of virtually all organ systems; however, the most frequent localizations are lung and kidney with pulmonary haemorrhage and rapidly progressive glomerulonephritis being the most severe manifestations [1] . Granulomatous involvement of the ear, nose and throat (ENT) system and of the lung is a frequent clinical feature of GPA and may represent the only localization in subgroups of patients [1] . Because of the frequent clinical overlap, GPA and MPA have been historically considered different ends of the same disease spectrum and therefore included together in clinical trials [2] . ANCA positivity is a feature of ∼90% of GPA and MPA patients; ANCA is usually tested using indirect immunofluorescence, where two main patterns are observed, cytoplasmic (C-ANCA) and perinuclear (P-ANCA), and then confirmed using ELISA, which in most cases shows reactivity against proteinase 3 (PR3) or myeloperoxidase (MPO). GPA is usually associated with C-ANCA, directed against PR3, whereas MPA with P-ANCA, directed against MPO [3] ; however, a significant overlap does exist with regard to the ANCA status; therefore although ANCA are often used to confirm the diagnosis of AAV, ANCA specificity towards PR3 or MPO cannot be used to identify GPA versus MPA [4] . In EGPA, the main disease characteristics are asthma, peripheral eosinophilia, ENT involvement and eosinophil-rich lung infiltrates; vasculitic manifestations (e.g. glomerulonephritis, peripheral neuropathy and purpura) are less prevalent than in GPA and MPA and they appear to be more frequent in the 40% of EGPA patients that are ANCA-positive [3, 5] .
Several candidate gene approach studies have been performed over the years; however, the understanding in the field of AAV genetics has dramatically increased after the publication of two genome-wide association studies (GWASs). The philosophy behind the GWAS is the interrogation of a high number of single-nucleotide polymorphisms (SNPs) that cover a big proportion of the human genome. This approach may be very informative; however, to avoid spurious associations, a very stringent P-value is required forcing a multicentre approach with big cohorts of patients. Two GWASs have been performed in AAV: the first conducted by the European Vasculitis Genetic Consortium (EVGC; 2687 cases of GPA and MPA, as well as 6858 controls) [6] and the second by the US Vasculitis Clinical Research Consortium (VCRC; 987 GPA cases and 2731 controls) [7] .
In this review, we will discuss the main genetic associations that have emerged in AAV, and what they have added to our understanding of vasculitis. Tables 1 and 2 summarize the main genetic associations in AAV derived from non-GWAS and GWAS, respectively.
G E N E T I C A S S O C I AT I O N S W I T H A AV S

HLA region
The role of the HLA region in autoimmunity is central. Several associations with different HLA SNPs have been shown, for instance, in rheumatoid arthritis and type 1 diabetes [24, 25] . When acting as risk factors, HLA SNPs may promote positive selection of autoreactive T cells or prevent their negative selection [26] .
The strongest evidence of HLA association in AAV is with the HLA-DPB1. This association has been initially described in a cohort of 150 German GPA patients (P = 1.51 × 10 −10 , OR 3.91) [27] and subsequently confirmed in an independent group of 108 German GPA patients [28] ; in a further analysis of the combined cohort, the association remained significant only in the ANCA-positive patients (P = 1.26 × 10 −22 ). This finding was then confirmed by the results of both GWASs: a strong association of an SNP in the HLA-DPB1 area (OR 3.67, P = 1.5 × 10 −71 ) resulted from the EVGC GWAS [6] as well as from the VCRC GWAS (OR 0.24, P = 1.91 × 10 −50 ) [7] . The different directions of the OR observed between the two studies may be related to the different SNPs interrogated, the frequencies of each SNP minor allele in patients and controls or the modality of data analysis; nevertheless, both studies indicate a highly significant association between AAV and variations within HLA-DPB1.
Interestingly, a sub-analysis of the EVGC GWAS also showed that this association was stronger in the PR3-ANCA-positive subgroup (P = 6.2 × 10 −89 ), independently of the clinical diagnosis, while this was not confirmed in the MPO-ANCA-positive subgroup. In the latter, a further analysis revealed an association with an SNP in the HLA-DQ region (P = 2.1 × 10 −08 ), which had probably been masked by the small number of MPO-ANCApositive patients in the primary analysis. This finding was further confirmed in an independent cohort of Italian cases [6] .
Other associations have been described in small or not replicated studies. In a Dutch cohort of 241 patients with GPA, a lower proportion of HLA-DR13(6) and HLA-DR1 and an increased proportion of HLA-DR4 were found compared with controls [29] ; no replication of these data has been published so far. In two small cohorts of 32 African-American and 74 Caucasian patients, an association with HLA-DRB1 was documented in PR3-ANCA-positive patients, but not in the MPO-positive ones [30] ; interestingly, an association with a variation in the same HLA locus has been documented in a cohort of 152 Chinese patients with GPA and MPA [31] . Relatively small studies documented an association of GPA with HLA-B50, HLA-DR1, HLA-DR9, HLA-DQw7 and HLA-DR3 [32] [33] [34] .
In MPA, few data are available; the most interesting report is from a group of 50 MPO-ANCA-positive Japanese patients, where an association with the HLA-DRB1*0901 (P = 0.033) and HLA-DQB1*0303 (P = 0.022) was documented. The small numbers and the high linkage disequilibrium between the two alleles (D 0 0.95, r 2 = 0.82) did not allow the identification of the independent variant [11] . Quite interesting is the confirmation of the association of the HLA-DQB1 with anti-MPOpositive patients emerged from the EVGC GWAS in a third cohort of different ethnicity. A study performed with 107 Chinese patients with MPA showed another potential association with HLA-DRB1*1101 (P = 0.023) [31] ; further studies will need to clarify if this is a genuine association or only expression of a non-random inheritance of this allele as part of a haplotype with a specific HLA-DQB1.
In EGPA, the most robust association that has emerged so far is that with HLA-DRB4; this has been shown in an Italian study with 48 patients (OR 2.49, P = 0.000232) [13] and has been replicated in an independent study of 102 German EGPA subjects (OR 1.87, P = 0.0002) [12] .
In summary, the findings of an association for all AAVs with SNPs in the HLA region have confirmed the existence of a likely autoimmune component in their pathogenesis. Different loci in the HLA region seem to be involved in the different AAV subtypes, thus suggesting that they have a distinct genetic background. Moreover, the results of the EVGC GWAS seem to support a genetic distinction between AAV forms, which is more closely related to ANCA specificity rather than to the clinical diagnosis.
PRTN3-SERPINA1 genes
The presence of autoantibodies against the neutrophil serum protease PR3 suggested its potential role in the development of GPA. PR3 may be stored in the neutrophil azurophilic granules as well as exposed on the neutrophil cell membrane [35] . Interestingly, PR3 surface expression is bimodal, with the antigen present on the surface of a proportion of the All genetic association studies on MPA and EGPA were reported, whereas for GPA we only included studies with a sample size of >400 patients.
F U L L R E V I E W G e n e t i c s o f A N C A -a s s o c i a t e d v a s c u l i t i s
neutrophils (defined as mPR3+), but not on all of them (mPR3−). The membrane-bound form is the one able to interact directly with the ANCA [36] , precipitating neutrophil activation and their endothelial adhesion. Neutrophil priming is a key process in order to increase surface expression of PR3 in the subgroup of mPR3+ neutrophils [37] , but the proportion of mPR3+ and mPR3− cells remains stable over time. A phenotype with a high proportion of mPR3+ neutrophils is more frequent in patients with AAV when compared with controls (85 versus 55%) [38] . These observations, together with the demonstration of the high stability over time of the ratio of mPR3+/mPR3− neutrophils in controls (r = 0.94) and the high concordance of this proportion in monozygotic twins (r = 0.99) but not in dizygotic twins (r = 0.06) [39] , have suggested that the cell surface expression of PR3 is genetically determined.
A non-replicated study that screened the coding and promoter sequences of PRTN3 (the gene encoding PR3) in 79 GPA patients and 129 controls demonstrated an association between the disease and an SNP of the promoter region (A564G) affecting a transcription factor-binding site (OR 4.2, P < 0.00001) [40] . The association of the PRTN3 gene SNP rs62132295 has also been interrogated in the EVGC GWAS, where a subgroup analysis revealed that it was significantly associated with GPA (OR 0.78, P = 2.6 × 10
−5
). As observed for the above-mentioned HLA association, the strength of the PRTN3 SNP signal increased in the PR3-ANCA-positive subgroup, independently of the clinical diagnosis (OR 0.73, P = 2.6 × 10
−7
). No association with PRTN3 emerged in the MPO-ANCA-positive patients [6] , which indicates a role for PRTN3 only in the pathogenesis of anti-PR3-positive AAV.
PR3 is also central in mediating direct tissue damage after neutrophil activation has occurred and the enzyme is released from the cell. Alpha-1 antitrypsin, encoded by the gene SERPINA1 on chromosome 14, represents the major inhibitor of PR3 activity. Two alpha-1 antitrypsin alleles, Z and S, have been described as associated with low enzymatic activity; studies in small cohorts suggested an association of both of these alleles with GPA [41] [42] [43] . The mechanism behind this was, and still is, unclear: it has been proposed that an enhanced reactivity of the immune system against an insufficiently cleared PR3 might play a central role [44] ; however, other evidence draws attention to the insufficient inhibition of the PR3 protease activity in peripheral tissues as responsible for more severe damage rather than a role as a proper risk factor for the development of the disease [45] . The largest study performed in the pre-GWAS era screened 433 Caucasian patients with GPA and 421 controls, and compared the frequency of the Z and S alleles, showing in 10 patients carrying the SS, ZZ or SZ genotypes an OR for the development of GPA of 14.58 (P = 0.002); the small number of cases was responsible for a broad confidence interval, suggesting caution in the interpretation of these findings [46] . In this context, significant results came from the results of the EVGC GWAS, which showed the association of a SNP in the SERPINA1 gene with AAVs (OR 0.59, P = 2.4 × 10
−9
). As per PRTN3 findings, this association was stronger in GPA patients (OR 0.54, P = 4.4 × 10 −10 ) and even more significant in the PR3-ANCApositive subgroup, independently of the clinical diagnosis (OR 0.53, P = 5.6 × 10 −12 ) [6] . The tag SNP identified in the GWAS is in linkage disequilibrium with the Z allele, confirming that this can be a risk factor for the development of the disease.
Fine mapping of the PRTN3 and SERPINA1 area is required for a better understanding of the genetic variations responsible for the risk of developing GPA and for further improvement in the pathogenic understanding.
Other replicated associations-PTPN22 and CTLA4
The interaction between ANCA and neutrophils is a central pathogenetic event in AAV. However, this represents only one component of a more complex picture. The role of B cells is also pivotal, as shown by the effectiveness of the anti-CD20 agent rituximab as a therapeutic option [47] . ANCA production is one of several B cell functions in AAV; these cells also provide T-cell support acting as antigen-presenting cells and are able to produce pro-inflammatory cytokines [48] . T-cells are also heavily involved as proven by their general hyperactivity in AAV and by the prominent role of the CD4 + T effector memory cells in causing endothelial damage [49] . It is therefore not surprising that SNPs within genes encoding B-and T-cell-specific proteins have been identified as potential risk factors for AAV.
The gene PTPN22 encodes the lymphoid tyrosine phosphatase (Lyp). Abnormal regulatory CD4 T-cell (T reg ) function, increased humoral activity [50] and enhanced neutrophil functions [51] have been described as features of the 620W PTPN22 variant; its role in AAV seemed indeed reasonable and provided the basis for the three main PTPN22 genetic association studies performed so far. The first, which included a German cohort of 199 GPA patients and 399 controls, showed an association of this variant with the disease (OR 1.75, P = 0.002); the association was even more significant in the ANCA-positive subgroup (OR 2.01, P = 0.0002) [19] . This result has been subsequently replicated in two independent cohorts of 641 British (OR 1.40, P = 1.4 × 10 −4 ) [9] and 344 Italian AAV patients [20] . Interestingly, the latter study showed that the association was restricted to the 143 GPA patients (OR 1.91, P = 0.005), but that the frequency of the 620W PTPN22 variant was comparable between the controls (n = 945) and the 102 MPA (P = 0.1072) or the 99 EGPA patients (P = 0.1508). The GPA population was PR3-ANCApositive in nearly 80% of the cases, whereas the MPA subgroup was MPO-ANCA-positive in ∼90%.
CTLA4 is an inhibitory glycoprotein expressed on activated T cells, which competes with the co-stimulatory molecule CD28 for the binding of CD80 or CD86 on the antigenpresenting cells [52] . The monoclonal antibody abatacept, whose efficacy in controlling disease activity was demonstrated in a recent trial in GPA patients with non-severe manifestations [53] , contains the binding domain of CTLA4, thus reducing the interaction CD28-CD80/CD86 and therefore T-cell stimulation. A role for genetic variants in the CTLA4 gene or other genes involved in its pathway may therefore be of interest in AAV [54, 55] . The more robust finding so far involves the SNP rs3087243, interrogated in two large cohorts of British patients; the first study found an association in 222 AAV patients (P = 0.0001) [56] , and the second confirmed it in an independent cohort of 641 AAV patients (P = 6.4 × 10
) [9] .
Other associations
The VCRC GWAS in AAV identified a potential association of GPA with the gene SEMA6A (P = 2.09 × 10 −8 ) encoding the protein semaphorin 6A [7] . The function of the proteins belonging to this family is unclear, but it has been proposed that they may be involved in immune regulation [57] . The association between the rs26595 SNP of the SEM6A gene and GPA was recently investigated also in a different cohort of Northern European patients, including 879 GPA, 150 MPA and 191 EGPA [58] . No statistically significant difference in allele frequencies was observed in this group, suggesting the necessity of further studies to better clarify the role of this region in AAV.
IL10 is a cytokine with anti-inflammatory activity. A study performed on 32 patients and replicated on 125 additional cases proposed an association of its (−1082) SNP in GPA [59, 60] ; interestingly, the latter report showed a signal for the same SNP in 36 MPA patients (P < 0.00001) [60] . A subsequent, larger study performed on 403 German GPA patients did not confirm this finding, but showed an association with a specific IL10 haplotype (P = 0.0003) in 75 patients with ANCA-negative EGPA [14] .
The high-affinity IL2 receptor, encoded by the gene IL2RA, is expressed not only on activated T cells, but also on activated B cells, NK cells and monocytes [61] . A normal IL2-IL2RA pathway is central for a physiological function of the immune system and for the development of a normal T reg repertoire [62] . A weak association (P = 0.0122) has been documented in 670 British patients with AAV for the SNP rs41295061 [15] ; replication in an independent cohort is required before considering this SNP as a potential risk factor.
CD226 is an adhesion molecule belonging to the immunoglobulin superfamily. In vitro stimulation of CD226 potentiates NK-mediated cytotoxicity [63] and provides a positive costimulatory signal for T-cell proliferation. An association between CD226 and GPA was documented in two distinct cohorts of 520 and 122 German GPA patients (respectively, OR 1.2; P = 0.020 and OR 1.37, P = 0.020); however, further replication failed in 105 British GPA patients [8] . A further independent replication study on a cohort of 641 British AAV cases found no association (P = 0.21) [9] . Interestingly, the two populations were of similar size and showed similar frequency of the SNP analysed (0.47 versus 0.50), suggesting as unlikely a different effect of the SNP in these populations.
Fc gamma receptors (FCGRs) are a group of proteins expressed on the surface of different cell types with different affinity for the Fc portion of different IgG subclasses [64] , suggesting a reasonable potential role for FCGRs in AAV. However, the genes encoding these receptors are located in a highly variable area (locus 1q23.3), whose genotyping has proven challenging due to high variability in terms of SNPs and copy number variations (CNVs) [64] . A Dutch study identified a SNP of FCGR2A and FCGR3A as potential risk factors for GPA in a cohort of 91 patients [65] , but the finding was not confirmed, at least for the FCGR2A SNP, in a cohort of 107 British patients [66] . CNVs of FCGR3B have been investigated in two cohorts of patients with contrasting results: an association was documented using qPCR in 80 UK patients with GPA and replicated in 77 French and 76 MPA patients [23] . However, this was not confirmed in 567 AAV patients when a different approach was used ( paralogue ratio test) [67] . The availability of new genotyping techniques will shed light on the potential association of this complex area with AAV.
Interferon regulatory factor 5 (IRF5) is a transcriptional factor able to induce transcription of IFN-alpha mRNA [68] . A large association study on 644 GPA failed to identify an association between IRF5 SNPs and disease; however, a potential protective haplotype was identified (P = 0.0012) [16] . Interestingly, one of these SNPs (rs10954213) has been recently identified as in association with MPO-ANCA-positive AAV in 177 Japanese patients (OR 1.27, P = 0.023) [69] .
A well-established role in the development of AAVs is played by infection. Any chronic infection, particularly nasal carriage of Staphylococcus aureus, is considered a potential trigger of the disease [70] . Toll-like receptors (TLRs) are a group of proteins able to recognize microbiological structures and activate immune responses. SNPs of TLR9 have been shown to be associated with GPA, MPA and PR3-associated AAV in a cohort of 863 AAV patients; however, the findings were not replicated in a small independent cohort. Interestingly, MPO-ANCA-positive disease was associated with the contrary allele compared with the PR3-ANCA subset, leading to a significant difference between the two groups for the SNP rs352140 (P = 0.000016) [21] . Defensins are cationic proteins characterized by intrinsic antimicrobial activity [71] ; a weak association between CNVs of the defensin gene DEFB4 and GPA has been documented in a small cohort of Chinese patients [72] .
Few further associations have been documented so far. In a cohort of 460 GPA patients, an association with a leptin SNP was found and replicated in 226 patients (OR 0.72 P = 0.0013); interestingly, genotyping of the same SNP in 196 EGPA patients confirmed the association but with contrasting allele distribution (OR 1.41, P = 0.0067) [10] . A small Japanese study identified a weak association between a leucocyte immunoglobulin-like receptor (LILRA2) and MPA (P = 0.049) [18] ; finally, genetic variants of genes encoding complement proteins C3F and C4A3 have been associated with AAV in 67 patients [73] .
G E N E T I C F I N D I N G S A N D D I S E A S E P H E N OT Y P E S
Genetic studies have been fundamental for the understanding of AAV so far. They have confirmed that the single disease entities grouped under the umbrella of AAV may reasonably be considered distinct diseases also because of their different genetic background. Moreover, it is now quite clear how GPA and MPA may be more correctly re-defined according to the ANCA specificity (PR3 versus MPO) rather than on the basis of their clinical phenotype. This is not surprising since several clinical findings were already pointing towards that direction, such as the different prognosis associated with anti-PR3 or anti-MPO ANCA positivity [74] as well as the different cardiovascular risk between these groups and the higher proportion of extrarenal manifestation in anti-PR3-positive patients [75] [76] [77] [78] [79] [80] [81] (Table 3) . These studies have also confirmed the central role of autoimmunity in AAV, as evidenced by the strong association with HLA and SNPs typical of other autoimmune diseases. More detailed are at the moment the evidences available for GPA-easier to study given its higher prevalence-where a crucial role has been shown also for the autoantigen PR3 and for its main inhibitor alpha-1 antitrypsin.
Although very informative, all these findings represent only the beginning of a new exciting and dynamic phase in this field. The next step will be to analyse larger GWASs or association studies in patients with anti-PR3 and anti-MPO AAV as separate entities in order to be more powered for the identification of further antibody-specific associations. The collection of larger cohorts or the metanalysis of data deriving from different existing cohorts will probably be of help also in identifying predisposing variants shared by the different ANCA subsets, which is quite expected given the significant clinical overlap between anti-PR3 and anti-MPO AAVs. The enrolment of patients in national and international registries characterized by long follow-up and detailed clinical data will make longitudinal studies possible for the identification of genetic predictors of disease severity and clinical outcome. A GWAS in EGPA is definitely warranted to allow an improvement in the understanding of the disease and only the cooperation of several centres will allow a sufficiently powered approach. We should not forget that the identification of an association between a tag SNP and a disease could be flag of an association present somewhere in the identified area, but potentially related to other variants in linkage disequilibrium with the SNP analysed. Fine mapping approaches are therefore necessary for the identification of the real associations and this may, in the long term, allow for the development of more targeted therapeutic approaches.
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